Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine Tumors — RFANET  

Neuroendocrine Tumor Grade 1 Clinical Trial

Official title: Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Low Grade Pancreatic Neuroendocrine Tumors of Less Than 2cm in Size

Status Recruiting

Clinical Trial Summary

Pancreatic radiofrequency ablation (RFA) could therefore be an alternative to the monitoring of pancreatic neuroendocrine tumors (PNETs) and more particularly nonfunctioning PNETs (NF-PNETs), which is costly and anxiety-inducing for patients. To date, only a few small studies have evaluated this treatment and the results are encouraging. It appears necessary to consider a large-scale study to ensure the efficacy and low morbidity of pancreatic RFA applied to PNETs.

Clinical Trial Description

The primary objective of the study is to evaluate the efficacy of radiofrequency treatment of grade 1 NF-PNETS with a size less than or equal to 2cm. Patients meeting the selection criteria will be included in the study after signing the consent. They will benefit from a RFA treatment consisting of 1 to 3 sessions depending on their response to the treatment. Patients will then be followed for 5 years in order to evaluate their response to treatment, their clinical evolution, their quality of life and any complications. ;

Related Conditions & MeSH terms

• Neoplasms
• Neuroendocrine Tumor Grade 1
• Neuroendocrine Tumor of Pancreas (Disorder)
• Neuroendocrine Tumors
• Pancreatic Neoplasms

• NCT number: NCT04520932
• Study type: Interventional
• Source: Institut Paoli-Calmettes
• Contact: Dominique GENRE, MD
• Phone: +33491223778
• Email: drci.up@ipc.unicancer.fr
• Status: Recruiting
• Phase: N/A
• Start date: March 30, 2021
• Completion date: April 2031